Low-Protein Hydrolysed Infant Formula for CMPA Infection Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cow's milk protein allergy (CMPA) in infants leads to increased risk of infections and weight gain issues, and existing infant formulas with higher protein content may exacerbate these problems.
Innovation Solution
An extensively hydrolysed infant formula with reduced protein content and supplemented with human milk oligosaccharides (HMOs) such as 2'-fucosyllactose and lacto-N-neotetraose, along with a lower proportion of medium chain triglycerides, to support growth and reduce infection risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If higher protein content infant formula is used, then growth and development needs are met, but weight gain and adipogenic activity increase
Solution Approach 1:
The patent changes the protein content parameter from conventional higher levels to a reduced level of 2.0-2.4 g per 100 kcal, while compensating with optimized fat composition (including MCTs) and carbohydrate sources to maintain adequate energy intake and support growth without excessive weight gain
Solution Approach 2:
The patent applies different quality characteristics to different macronutrients: using medium chain triglycerides (MCTs) specifically for their rapid energy provision and lower adipogenic effect, while controlling overall protein quantity, creating a localized nutritional approach that addresses weight gain concerns without compromising growth
2Quantity of substance
If higher protein content infant formula is used, then adequate nutrition is provided, but infection risk increases
Solution Approach 1:
The patent reduces protein content to 2.0-2.4 g per 100 kcal and combines this with specific fat composition (including MCTs at 10-30% of total fat) and carbohydrate sources to create a nutritional profile that supports immune function and reduces infection risk while maintaining adequate nutrition
Solution Approach 2:
The patent creates a composite nutritional formulation combining reduced protein with specific fat sources (including MCTs) and carbohydrates, where the synergistic effect of this composite composition provides both adequate nutrition and infection protection, addressing the harmful effect without sacrificing nutritional adequacy
3Weight of moving object
If reduced protein content formula is used, then weight gain and infection risk are reduced, but growth and development may be compromised
Solution Approach 1:
The patent optimizes multiple macronutrient parameters simultaneously: reducing protein to 2.0-2.4 g/100 kcal while increasing fat content (particularly MCTs at 10-30%) and adjusting carbohydrate composition to maintain total energy intake and support growth trajectories without excessive weight gain
Solution Approach 2:
The patent uses medium chain triglycerides (MCTs) as a multi-functional fat source that provides rapid energy for growth, supports brain development, and has lower adipogenic effect compared to other fats, allowing the formula to support growth while controlling weight gain at the same time
Data Source
Figure 1
Figure 2
Figure 3
AI summary
An infant formula for use in reducing the occurrence of, or preventing, an infection in an infant, wherein the infant formula is an extensively hydrolysed infant formula (eHF) or an amino acid- based infant formula (AAF), wherein the infant formula comprises protein, carbohydrate and fat, wherein the eHF comprises about 2.4 g or less protein per 100 kcal, or the AAF comprises about 2.9g or less protein per 100kcal, wherein the infant formula further comprises 2'- fucosyllactose (2'FL) and/or lacto-N-neotetraose (LNnT), and wherein about 30% or less by weight of the fat is medium chain triglycerides (MCTs).